Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2022-07-01
|
| Collection: | Microbial Cell Factories |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s12934-022-01873-7 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|